Nirupa J Raghunathan1, Emily C Zabor2, Nassim Anderson3, Kevin Oeffinger4, Emily S Tonorezos3,5, Deborah Korenstein3,5. 1. Department of Medicine, Memorial Sloan Kettering Cancer Center, 485 Lexington Ave, 2nd Floor, New York City, NY, 10017, USA. raghunan@mskcc.org. 2. Department of Quantitative Health Sciences, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA. 3. Department of Medicine, Memorial Sloan Kettering Cancer Center, 485 Lexington Ave, 2nd Floor, New York City, NY, 10017, USA. 4. Duke Cancer Institute, Durham, NC, USA. 5. Weill Cornell Medicine, New York City, NY, USA.
Abstract
PURPOSE: Childhood, adolescent, and young adult cancer survivors treated with radiation therapy (RT) may be unaware of their high cardiovascular disease (CVD) risk or how to mitigate it. Tools are needed to improve understanding. We developed and pilot-tested a risk communication tool for shared decision-making with survivors regarding CVD risk reduction with statin therapy. We included quantitative and qualitative arms to further tool development and testing. METHODS: The statin risk communication tool was adapted from a previously validated tool. Patients were at increased risk for CVD due to history of chest RT and recruited to usual care and intervention arms. The post-visit survey included Likert-like scales to explore acceptability of the tool, knowledge questions, and a decisional conflict scale. This pilot study used descriptive statistics and was not powered for significance. Semi-structured interviews with intervention arm participants explored shared decision-making processes. RESULTS: Median participant (n = 46) age was 45. Most intervention patients (22/24, 92%) and 50% (11/22) of controls found statin information acceptable while 31% (7/22) of the control arm selected "not applicable" regarding information acceptability. Most participants were unaware of their personal CVD risk or potential statin side effects. In semi-structured interviews, participants found the tool is helpful to visualize risk and aid conversations. CONCLUSIONS: The risk communication tool was acceptable. Qualitative data suggested the tool improved decisional clarity and comfort. IMPLICATIONS FOR CANCER SURVIVORS: Poor knowledge of CVD and statins and poor recall of CVD risk conversation suggest a need to continue to optimize conversations regarding cardiovascular risk and statin therapy.
PURPOSE: Childhood, adolescent, and young adult cancer survivors treated with radiation therapy (RT) may be unaware of their high cardiovascular disease (CVD) risk or how to mitigate it. Tools are needed to improve understanding. We developed and pilot-tested a risk communication tool for shared decision-making with survivors regarding CVD risk reduction with statin therapy. We included quantitative and qualitative arms to further tool development and testing. METHODS: The statin risk communication tool was adapted from a previously validated tool. Patients were at increased risk for CVD due to history of chest RT and recruited to usual care and intervention arms. The post-visit survey included Likert-like scales to explore acceptability of the tool, knowledge questions, and a decisional conflict scale. This pilot study used descriptive statistics and was not powered for significance. Semi-structured interviews with intervention arm participants explored shared decision-making processes. RESULTS: Median participant (n = 46) age was 45. Most intervention patients (22/24, 92%) and 50% (11/22) of controls found statin information acceptable while 31% (7/22) of the control arm selected "not applicable" regarding information acceptability. Most participants were unaware of their personal CVD risk or potential statin side effects. In semi-structured interviews, participants found the tool is helpful to visualize risk and aid conversations. CONCLUSIONS: The risk communication tool was acceptable. Qualitative data suggested the tool improved decisional clarity and comfort. IMPLICATIONS FOR CANCER SURVIVORS: Poor knowledge of CVD and statins and poor recall of CVD risk conversation suggest a need to continue to optimize conversations regarding cardiovascular risk and statin therapy.
Authors: Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson Journal: J Am Coll Cardiol Date: 2013-11-12 Impact factor: 24.094
Authors: Daniella A Zipkin; Craig A Umscheid; Nancy L Keating; Elizabeth Allen; KoKo Aung; Rebecca Beyth; Scott Kaatz; Devin M Mann; Jeremy B Sussman; Deborah Korenstein; Connie Schardt; Avishek Nagi; Richard Sloane; David A Feldstein Journal: Ann Intern Med Date: 2014-08-19 Impact factor: 25.391
Authors: Christopher M Gamboa; Monika M Safford; Emily B Levitan; Devin M Mann; Huifeng Yun; Stephen P Glasser; J Michael Woolley; Robert Rosenson; Michael Farkouh; Paul Muntner Journal: Am J Med Sci Date: 2014-08 Impact factor: 2.378
Authors: Gregory T Armstrong; Qi Liu; Yutaka Yasui; Joseph P Neglia; Wendy Leisenring; Leslie L Robison; Ann C Mertens Journal: J Clin Oncol Date: 2009-03-30 Impact factor: 44.544